Tumor suppressor promotes FLT3-ITD AML



AML cells
New research indicates that RUNX1, a known tumor suppressor, actually cooperates with internal tandem duplications in the FLT3 receptor tyrosine kinase (FLT3-ITD) to induce acute myeloid leukemia (AML). Investigators say this discovery suggests that blocking RUNX1 activity will “greatly enhance” current therapeutic approaches using FLT3 inhibitors. The discovery was published in The Journal... [Read Article]

Model illustrates progression to MDS, AML



Induced pluripotent stem cells
Image by James Thomson
Researchers say they have created a model that shows the step-by-step progression from normal blood cells to acute myeloid leukemia (AML). The team generated induced pluripotent stem cell (iPSC) lines capturing disease stages that included preleukemia, low-risk myelodysplastic syndrome (MDS), high-risk MDS, and AML. The researchers then used... [Read Article]

Site of care may impact survival for AYAs with ALL, AML



Young adult with cancer receiving chemotherapy
Photo by Rhoda Baer
Receiving treatment at specialized cancer centers may improve survival for adolescents and young adults (AYAs) with acute leukemia, according to a study published in Cancer Epidemiology, Biomarkers & Prevention. The study showed that, when patients were treated at specialized cancer centers, survival rates were similar... [Read Article]

Styrene exposure linked to myeloid leukemia, HL



Wind turbines in Styria, Austria. Styrene is used in the manufacture of wind turbines.
A new study links styrene—a chemical used in the manufacture of plastics, rubber, and resins—to certain cancers. The research showed that, contrary to previous suggestions, employees who have worked with styrene do not have an increased incidence of esophageal, pancreatic,... [Read Article]